Henrik Boye Jensen

Publications (2) View all

• Source

  Available from: Egon Stenager

  Article: [Aminopyridines for symptomatic treatment of multiple sclerosis].

  Henrik Boye Jensen, Egon Stenager, Mads Henrik Ravnborg
  [show abstract] [hide abstract]
  ABSTRACT: 3,4-diaminopyridine (DAP) and 4-aminopyridine (AP) block potassium channels and can improve action potentials in demyelinated nerve fibres. We identified ten randomised placebo-controlled trials investigating AP/DAP as symptomatic treatment in multiple sclerosis. There is evidence that AP and DAP improve muscle strength in the lower extremities and that AP increases walking speed, and it might improve Expanded Disability Status Scale scores, spasticity and fatigue. There is a lack of evidence-based guidelines of treatment and studies investigating the effect on participation/activity and quality of life.
  Ugeskrift for laeger 12/2011; 173(50):3259-63.
• Article: [CADASIL versus multiple sclerosis].

  Alan Christian Kimper-Karl, Henrik Boye Jensen, Ole Kristensen
  [show abstract] [hide abstract]
  ABSTRACT: This case history reports on the second family in Denmark to be diagnosed with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy). Due to symptoms, signs and paraclinical findings, an initial diagnosis of multiple sclerosis was made. However, MRI findings of leucoencephalopathy in the external capsule and anterior temporal lobes together with negative CSF findings and family history raised suspicions of CADASIL. Skin biopsy with granular osmiophilic material (GOM) and genetic testing showing the NOTCH 3 mutation proved the diagnosis. There is considerable variability in the symptoms of CADASIL; however, most often a family history of migraine, cerebrovascular events and dementia in early life is found.
  Ugeskrift for laeger 03/2006; 168(7):702-3.